Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Biogen    BIIB

BIOGEN (BIIB)
Mes dernières consult.
Most popular
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
10/12/2017 10/13/2017 10/16/2017 10/17/2017 10/18/2017 Date
333.31(c) 337.64(c) 335.68(c) 344.47(c) 344.58(c) Last
1 120 224 1 360 299 1 176 589 1 616 264 1 247 013 Volume
+0.04% +1.30% -0.58% +2.62% +0.03% Change
More quotes
Financials ($)
Sales 2017 11 968 M
EBIT 2017 6 190 M
Net income 2017 3 849 M
Debt 2017 3 248 M
Yield 2017 -
Sales 2018 12 472 M
EBIT 2018 6 602 M
Net income 2018 4 431 M
Debt 2018 1 449 M
Yield 2018 -
P/E ratio 2017 19,30
P/E ratio 2018 16,21
EV / Sales2017 6,36x
EV / Sales2018 5,96x
Capitalization 72 832 M
More Financials
Company
Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders.Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for... 
Sector
Pharmaceuticals
Calendar
10/24 | 12:30pmEarnings Release
More about the company
Surperformance© ratings of Biogen
Trading Rating : Investor Rating :
More Ratings
Latest news on BIOGEN
01:31p BIOGEN : Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive ..
09/26 BIOGEN : to Report Third Quarter 2017 Financial Results on October 24, 2017
09/25 BIOGEN : Appoints Camille Lee as SVP, Alzheimer’s Disease Therapeutic Area
09/12 BIOGEN : Appoints Sanjay Jariwala as SVP, Worldwide Medical
09/06 BIOGEN : to Present at the Morgan Stanley 15th Annual Global Healthcare Conferen..
08/28 BIOGEN : Featured Company News - IMRALDI(R), Biogen's Version of AbbVie's Humira..
08/28 BIOGEN : Reports New Data from Phase 1b Study of Investigational Alzheimer&rsquo..
08/25 Samsung, Biogen version of AbbVie's Humira approved in Europe
08/25 BIOGEN : IMRALDI®, Biogen’s Adalimumab Biosimilar Referencing Humira®, is ..
08/18DJCorrection to Biogen Treads Tricky Path Between Politicians, Investors Articl..
More news
Sector news : Biopharmaceuticals
04:43p ALLERGAN : ruling casts doubt on tribal patent strategy
03:09pDJELI LILLY AND : Lilly To Develop Cancer Vaccine Products with CureVac -- Market ..
08:52aDJASTRAZENECA : Breast-Cancer Drug Gets Priority Review From FDA
08:48aDJACTELION : J&J Net Income Falls After Actelion Deal -- WSJ
08:24a RECKITT BENCKISER : to form two business units for better focus
More sector news : Biopharmaceuticals
4-Traders Strategies on BIOGEN 
BIOGEN IDEC  - 2014
Back on a stimulating support
BUY
BIOGEN IDEC - 2013
The bullish trend is not over
BUY
More Strategies
Latest Tweets
04:51pBiogen Inc. $BIIB Upgraded by Stifel Nicolaus to Buy  
03:15pBiogen shares hit two-year high after brokers turn bullish ahead of third qua.. 
01:55pBiogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive.. 
01:34pBiogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive.. 
01:33pBiogen Confirms Commitment to Tackle Multiple Sclerosis Through Comprehensive.. 
More tweets
Qtime:235
News from SeekingAlpha
10/17 VALUE SYSTEM : Amgen Looks Undervalued
10/17 Premarket analyst action - healthcare
10/16 President Trump at it again with comments on "out of control" drug prices
10/16 SANOFI : Upward Trajectory In 2017
10/13 ROCHE AND ALLERGAN : Approaches To Alzheimer's
Chart BIOGEN
Duration : Period :
Biogen Technical Analysis Chart | BIIB | US09062X1037 | 4-Traders
Technical analysis trends BIOGEN
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 29
Average target price 344 $
Spread / Average Target -0,04%
EPS Revisions
Managers
NameTitle
Michel Vounatsos Chief Executive Officer & Director
Stelios B. Papadopoulos Chairman
Alisha A. Alaimo Senior Vice President-US Therapeutic Operations
Gregory F. Covino VP-Finance, Chief Financial & Accounting Officer
Alfred W. Sandrock Chief Medical Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
BIOGEN28.45%72 832
CSL LIMITED37.10%49 366
ALEXION PHARMACEUTICALS14.92%31 951
GRIFOLS SA27.81%17 858
BIOMARIN PHARMACEUTICAL14.82%16 395
CHONGQING ZHIFEI BIOLOGICAL PRDCT CO LTD--.--%6 795